menu
    • menu
    [{"orgOrder":0,"company":"Aska Pharmaceutical","sponsor":"Aska Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Aska Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aska Pharmaceutical \/ Aska Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Aska Pharmaceutical \/ Aska Pharmaceutical"},{"orgOrder":0,"company":"Aska Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Relugolix","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Aska Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aska Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aska Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Aska Pharmaceutical","sponsor":"KinoPharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"RKP00156","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Aska Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aska Pharmaceutical \/ Aska Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Aska Pharmaceutical \/ Aska Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Aska Pharmaceutical

    Menu

    Aska Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aska Pharmaceutical

                            Japan arrow
                            AES
                            Not Confirmed

                            Aska Pharmaceutical

                            Japan arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RKP00156

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Recipient : KinoPharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ASKA Pharmaceutical Co., Ltd. and KinoPharma, Inc. Enter into Option Agreement for Treatment of Cervical Dyspl...

                            Details : Under the agreement, ASKA will obtain a right to exercise an option to jointly develop with KinoPharma and to exclusively sell the drug in Japan.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 14, 2020

                            Lead Product(s) : RKP00156

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Recipient : KinoPharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aska Pharmaceutical

                            Japan arrow
                            AES
                            Not Confirmed

                            Aska Pharmaceutical

                            Japan arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifaximin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Yokohama City University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial

                            Details : Rifaximin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intestinal Pseudo-Obstruction.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            October 08, 2019

                            Lead Product(s) : Rifaximin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Yokohama City University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aska Pharmaceutical

                            Japan arrow
                            AES
                            Not Confirmed

                            Aska Pharmaceutical

                            Japan arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Relugolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With End...

                            Details : TAK-385 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Endometriosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 30, 2019

                            Lead Product(s) : Relugolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth